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Abstract The kinin system has been recognized as a locally
operating hormone system of cardiovascular cells, however, the
molecular mechanisms regulating circumscribed kinin release on
cell surfaces are not fully understood. In particular, the principal
cell docking sites for the kinin precursor, high molecular weight
kininogen (HK), are not fully explored. Here we demonstrate by
enzymatic digestion, recombinant overexpression, and affinity
cross-linking studies that cell surface chondroitin sulfate (CS)
chains of proteoglycans (PGs) serve as major HK binding sites
on platelet, fibroblast, liver, and endothelial kidney cells. In this
way, CS-type PGs may contribute to a local accumulation of
kinin precursors on cell surfaces and modulate circumscribed
release of short-lived kinin hormones at or next to their site of
action. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Kinins are short-lived peptide hormones of 9^11 amino
acids that serve as key regulators of local blood pressure
and in£ammatory responses by increasing intracellular Ca2
levels, stimulating nitric oxide production, and enhancing
prostaglandin biosynthesis [1]. Three major components reg-
ulate kinin production on surfaces of cardiovascular cells :
factor XII (Hageman factor), plasma prokallikrein and high
molecular weight kininogen (HK). These factors attach di-
rectly (factor XII, HK) or indirectly (prokallikrein via HK)
to physiological cell surfaces, as well as to arti¢cial surfaces
such as kaolin or certain polymers. Exposure of blood to
subendothelial structures (‘contact phase’) following disrup-
tion of the endothelial barrier, or secretion of proteases
from neutrophil granulocytes that attach to the endothelium,
initiate the conversion of small amounts of factor XII into its
active form, factor XIIa. Factor XIIa activates prokallikrein
to the active enzyme kallikrein, which, in turn, activates addi-
tional factor XII. Active kallikrein rapidly cleaves the tightly
associated HK with a resulting burst of bradykinin liberation
in proximity to its receptor [1].
Contact factors have been immunolocalized to the surface
of endothelial cells, neutrophils, platelets, vascular smooth
muscle cells, kidney epithelial cells, glandular duct cells, neu-
rons, and ¢broblasts [2]. HK binds to cell surfaces via two
segments on its D3 and D5H domains, and at the same time it
tethers prokallikrein to cells via a speci¢c binding site exposed
on domain D6H. Thus, HK serves as an adapter protein that
links proteolytic activity and kinin generation to the surface of
target cells. A search for HK acceptors has identi¢ed the
proteins Mac-1 [3], p33/gC1qR [4], thrombospondin-1 [5], gly-
coprotein-Ib [6], cytokeratin-1 [7], and urokinase receptor
(binds only to kinin-free HK) [8] as candidate binding pro-
teins. Though all of these proteins bind to HK in vitro, none
of them accounts for the high number of cellular HK binding
sites on eukaryotic cell surfaces (up to 107/cell) and their
ubiquitous occurrence [4,7^11].
We have recently identi¢ed heparan sulfate (HS) glycosami-
noglycans (GAGs) of proteoglycans (PGs) as major HK ac-
ceptors on endothelial cells [11]. Here, we demonstrate that
HK binds to yet another type of GAG, chondroitin sulfate
(CS). CS is the predominant GAG on most cell types other
than endothelial cells, and could provide a platform for con-
tact phase factors on most eukaryotic cells.
2. Materials and methods
2.1. HK binding assays
Con£uent cell monolayers were washed three times with phosphate-
bu¡ered saline (PBS). To degrade cell-bound HS- and CS-type GAG,
cells were incubated (30 min, 37‡C) with 1 U/ml of chondroitinase
ABC and/or a mixture of heparinase I and heparinase III (0.5 U/ml
each) in PBS supplemented with a protease inhibitor cocktail. Washed
cells were incubated (1 h, 37‡C) in 0.135 M NaCl, 2.7 mM KCl, 11.9
mM NaHCO3, 0.36 mM NaH2PO4, 14.7 mM HEPES, 3.5 mg/ml
dextrose, 50 WM ZnCl2, pH 7.35 (HEPES-Tyrode’s bu¡er, HT) con-
taining 1% (w/v) bovine serum albumin and 20 nM [125I]HK. Follow-
ing six washes, cell-associated [125I]HK was measured and normalized
for total cellular proteins [4]. Alternatively, binding of [125I]HK was
carried out in cell suspension [9]. To study the e¡ect of GAG on
[125I]HK binding to HEK293t cells, con£uent cells were incubated
with serial 1:2 dilutions of biotinylated HK (‘biot-HK’) in HT (start-
ing from 10 nM) supplemented with 500 nM HK, CS-A, HS, glucose
or HT (control). In vitro binding of 10 nM biot-HK to serial 1:2
dilutions (starting from 100 Wg/ml) in HT of HS, CS-A, -B or -C
(Sigma) was performed on poly-L-lysine-coated MaxiSorp1 microtiter
plates (Nunc). For competition experiments, CS-A (250 Wg/ml) was
chemically linked to CovaLink1 plates (Nunc) by 1-ethyl-3-(3-di-
methylaminopropyl)-carbodiimide [11]. Binding of 10 nM biot-HK
in HT to immobilized CS-A was quanti¢ed by the streptavidin^per-
oxidase method (Roche) in the presence of serial 1:2 dilutions of
maltose binding protein (MBP) fused to HK domain D3 (‘MBP^
D3’), MBP^D5H or unfused MBP (starting concentration 2 WM);
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 5 7 0 - 4
*Corresponding author. Fax: (49)-69-6301 5577.
E-mail: wme@biochem2.de
Abbreviations: CS, chondroitin sulfate; HK, high molecular weight
kininogen; HS, heparan sulfate; PBS, phosphate-bu¡ered saline
FEBS 24986 22-6-01 Cyaan Magenta Geel Zwart
FEBS 24986FEBS Letters 500 (2001) 36^40
antibodies to bradykinin (‘K-BK’), D3 (‘KLDC27’) or D5H
(‘KHKH20’) (2 WM); GAG (CS-A, -B, -C, HS), glucose or unlabeled
HK (200 Wg/ml).
2.2. Transient transfection of decorin and biglycan cDNAs
Decorin cDNA was cloned by reverse transcription-PCR [11] from
HF15 ¢broblast mRNA using 5P-primer, 5P-ATGGGATCCATCAT-
GAAGGCCACTATCATCCTCC-3P (nucleotide positions 214^247
referring to cDNA accession no. J02814) and 3P-primer, 5P-GAACC-
CGGGATAGTTTCCGAGTTGAATGGCAGAGCG-3P (positions
1273^1308). For cloning of the biglycan cDNA from mRNA of
EA.hy926 cells, we used 5P-primer, 5P-GGTGGATCCGCCATGTG-
GCCCCTGTGGCGCCTCG-3P (positions 109^142, accession no.
J04599) and 3P-primer, 5P-CTGCCCGGGCTTTTTGTAGTTGCCA-
AACTGGATGG-3P (positions 1199^1233). The 5P-primers introduce
a BamHI site 6 bp upstream of the AUG start codon, and the 3P-
primers replace the stop codon by a CCC triplet for an additional
SmaI site. An oligonucleotide encoding a double strand myc epitope
was ligated onto the 3P-end of the PCR product using the SmaI sites.
The resulting cDNAs were cloned into the pcDNA3.0 vector (Invi-
trogen) using BamHI and 3P EcoRI sites from the myc oligonucleo-
tide. The cDNA constructs (correct sequence veri¢ed by full-length
sequencing) were used to transfect COS-7 cells by DEAE-dextran or
HEK293t cells by lipofectamine (Life Technologies) techniques. HK
binding assays were performed 60 h after transfection. Transfection
e⁄ciency was s 50% as determined by co-transfection with a vector
encoding green £uorescent protein.
2.3. Immuno£uorescence
HK bound to HUVEC, KINS ¢broblasts and HEK293t cells was
immunolocalized with 20 Wg/ml of antibody I107 directed to the light
chain of HK as described [11]. Nuclear staining was done with 1%
(w/v) 4,6-diamidino-2-phenylindole (Sigma) before embedding in
N-propyl gallate.
2.4. Cross-linking and immunoprecipitation
COS-7 cells overexpressing myc-tagged decorin or biglycan were
three times PBS-washed, incubated (1 h, 4‡C) with 10 mM sodium
metaperiodate (Sigma) in 150 mM sodium acetate, pH 5.5. Oxidation
was terminated by adding glycerol to 15 mM and incubating for 5 min
at 4‡C. The hetero-bifunctional photoa⁄nity cross-linker p-azidoben-
zoyl-hydrazide (ABH, Pierce) was dissolved in DMSO at 250 mM,
and 50 Wl was added to the reaction mixture (¢nal ABH concentration
5 mM) followed by incubation (30 min, 37‡C) in the dark [12]. Cells
were washed six times with PBS in the dark, and a cell binding assay
using 20 nM [125I]HK was performed. The cross-linker was activated
with 10 £ashlights, the cells were six times PBS-washed, lysed in 1 ml
of RIPA bu¡er and centrifuged (14 000Ug, 15 min, 4‡C). The super-
natant was divided and subjected to immunoprecipitation using K-
myc or K-HK (I107) antibodies bound to protein G-Sepharose (Phar-
macia), respectively. Following centrifugation and washing three
times, immunoprecipitates were dissolved in SDS bu¡er, and analyzed
by SDS^PAGE and autoradiography [13].
3. Results
3.1. HK binding to various cell types
To analyze the interaction of HK with various cell types, we
employed a direct binding assay using [125I]HK in the pres-
ence of 50 WM Zn2 (Fig. 1). Speci¢c binding of [125I]HK to
cells was de¢ned as the di¡erence between the total binding
and the binding in the presence of a 250-fold molar excess of
HK cell binding domains D3 and D5H. The following rank
order for HK binding was obtained: HUVEC (set to
100%)sEA.hy926 (89%)sHEK293t (83%)sKINS ¢bro-
blasts (81%)s platelets (77%)sHepG2 (61%)sCOS-7
(52%)s erythrocytes (35%). In the absence of Zn2, speci¢c
binding was reduced 2^3-fold, for all cell types tested. Immu-
no£uorescence analysis with anti-HK antibodies revealed sim-
ilar staining patterns for HUVEC, ¢broblasts and HEK293t
cells (Fig. 1, inserts). Cell-bound HK was prevalent at the cell
surface and staining extended pericellularly into the extracel-
lular matrix. These results may indicate that various cell types
expose similar HK binding sites, albeit at varying copy num-
bers.
3.2. Docking of HK to the cell surface via CS-type PG
As we have previously identi¢ed the HS type of GAGs as
the major HK binding sites on endothelial cells, we wanted to
determine if the same structure may account for HK binding
by other cell types, and whether the most abundant GAG
type, CS [14], may be involved. To this end, we surface-di-
gested con£uent cells with chondroitinase ABC alone, or in
Fig. 1. Binding of HK to cell surfaces. Relative binding capacity for 20 nM [125I]HK on HUVEC (HUV), EA.hy926 (EA), platelets (pla),
erythrocytes (ery), HepG12 (Hep), KINS ¢broblasts (KIN), HEK293t (HEK), and COS-7 (COS) cells in the presence of 50 WM Zn2. Total
HK binding (dark columns) was arbitrary set at 100% for HUVEC. Unspeci¢c binding was determined in the presence of 500 nM MBP^D3
and MBP^D5H (light columns) or in the absence of Zn2 (gray columns). Means þ S.D. of three independent binding assays standardized to
1 Wg of cell protein are presented. Inserts: immunolocalization of HK bound to cultured HUVEC, KINS ¢broblasts and HEK293t cells. Mag-
ni¢cation U100.
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combination with heparinases I/III, and measured the
[125I]HK binding capacity of the treated cells (Fig. 2A). Con-
trols were done in the absence of enzyme (set at 100%). Chon-
droitinase treatment reduced HK binding to 43%, 50% and
73% of the control for KINS ¢broblasts, HEK293t, and
EA.hy926 cells, respectively. Co-incubation with heparinases
further lowered the binding capacity to 27%, 28% and 25%,
respectively, of the control. The chondroitinase-induced loss
of kininogen binding capacity was minor for endothelial cells
(27% decrease of binding), while the e¡ect of heparinase was
most pronounced on this cell type (48%). In contrast, chon-
droitinase treatment of KINS ¢broblasts resulted in a major
loss of HK binding capacity (57% decrease of binding), where-
as the e¡ect of heparinase was relatively minor (16%). Similar
results were obtained for HEK293t cells (Fig. 2A). Thus, CS-
type PG plays a major role as HK docking structures on
¢broblasts and embryonic kidney cells, but are of minor im-
portance for binding to endothelial cells.
To further substantiate a role for CS in HK binding, we
tested whether upregulation of cell surface CS-PG is paral-
leled by an increase in HK binding capacity. The prototypical
CS-type PG decorin and biglycan were transiently overex-
pressed in HEK293t and COS-7 cells. After 60 h, [125I]HK
binding capacity was tested (Fig. 2B). Mock-transfected cells
(set to 100% HK binding) were used as control. Overexpres-
sion of decorin raised HK binding capacity to 271% and 228%
for HEK293t and COS-7 cells, respectively, while overexpres-
sion of biglycan increased the HK binding capacity to 296%
and 235%, respectively (Fig. 2B). Surface digestion of PG
overexpressing cells using CS-ase resulted in a decrease in
HK binding of up to 39% compared to non-digested, mock-
transfected control cells. Thus, both loss-of-function and gain-
of-function experiments clearly point to CS GAG as major
HK acceptor sites on various cell types.
3.3. Speci¢city of HK binding to CS in vitro
To test the speci¢city of HK binding to CS, we used a
direct binding assay in which GAGs were covalently bound
to microtiter plates. Biot-HK speci¢cally bound to various CS
types with high a⁄nity (Fig. 3A). The apparent KD values
were 2.5 nM (CS-A), 3.5 nM (CS-B), and 10 nM (CS-C).
Binding to HS was used as a positive control (KD = 8 nM).
To test the speci¢city of HK binding to CS-A, we applied
competitors with apparent IC50 values of 3^14 nM (CS-A,
-B and -C), 8 nM (HS) and 2 nM (unlabeled HK) (Fig.
3B). Recombinant fusion proteins MBP^D3 (IC50 = 1.1 WM)
or MBP^D5H (200 nM), as well as antibodies KLDC27 (750
nM) and KHKH20 (85 nM) directed against the cell binding
segments of HK domains D3 and D5H, respectively, competed
with HK for CS binding (Fig. 3C). We also tested the specif-
icity of biot-HK binding to con£uent HEK293t cells. Soluble
CS at 500 nM reduced HK cell binding by s 60% at 10 nM of
biot-HK, as did HS and unlabeled HK but not glucose (Fig.
3D).
3.4. Cross-linking of HK to CS GAG
To demonstrate the physical interaction of HK with cell
surface-bound CS, we employed COS-7 cells that overexpress
myc-tagged decorin or myc-tagged biglycan CS-PG. Follow-
ing oxidation of the GAG the hetero-bifunctional photoa⁄n-
ity cross-linker ABH was attached to oxidized carbohydrates.
ABH-conjugated cells were incubated with 20 nM [125I]HK,
and cross-linking was induced with light. Cell lysates were
subjected to immunoprecipitation with anti-HK or anti-myc
antibodies. Autoradiography of the precipitates showed bands
migrating at 270^290 kDa, corresponding to the combined
molecular masses of [125I]HK bound to decorin-myc or bigly-
can-myc (Fig. 4). The heterogenity of the signals, typically for
PG, most likely re£ects heterogenity in the CS chains. Cells
that had been treated with CS-ase failed to produce any spe-
ci¢c bands (not shown). Additional high molecular weight
bands (migrating at s 500 kDa) may be cross-linked multi-
meric complexes of HK-decorin or HK-biglycan, and/or high
molecular mass PG bound to HK, however, we have not
experimentally addressed these possibilities. Altogether, our
data demonstrate a crucial role for CS-type PG in HK bind-
ing to cells.
4. Discussion
The binding of HK to cell surfaces is a crucial step in the
kinin-generating pathway since (i) it assembles two of the
three contact phase factors onto endothelial and epithelial
linings [1] ; (ii) docking to the cell surface protects HK from
proteolysis by kallikreins, preventing a constitutive release of
Fig. 2. Correlation of HK binding capacity and CS expression.
A: Relative binding of 20 nM [125I]HK to EA.hy926, KINS ¢bro-
blasts and HEK293t cells with or without prior treatment with
chondroitinase ABC (CS-ase) and/or heparinase I/III (HS-ase); un-
treated EA.hy926 cells are arbitrary given a binding capacity of
100%. B: [125I]HK binding to COS-7 and HEK293t cells transiently
overexpressing decorin (dec) or biglycan (big) or mock-transfected
cells (con), with or without prior treatment with chondroitinase
ABC (CS-ase). Means þ S.D. of three independent experiments are
presented.
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bradykinin [10] ; (iii) attachment to cell surfaces locates the
prohormone in close proximity to its receptors, increasing
the probability that short-lived bradykinin will trigger cellular
responses [15]. We have recently identi¢ed HS-type GAG as
the major HK docking structures on endothelial cells [11].
Our present ¢nding that CS are important HK acceptors for
many non-endothelial cells broadens and generalizes the con-
cept that PG anchors HK to most cells. Although the mode of
HK interaction with PG has not been addressed in molecular
detail, it appears reasonable to postulate that both CS- and
HS-PG bind to HK through their negatively charged GAG
portion. Most likely these carbohydrates interact electrostati-
cally with charged amino acid side chains that are abundant
in the His/Lys-rich region of the HK D5H domain [16].
Binding of (pre)hormones to GAG chains of PG appears to
be a common biological phenomenon. Basic ¢broblast growth
factor (bFGF), interferon-Q, and interleukins 7, 8, 10 and 12
attach to GAG on cell surfaces [17]. Based on these observa-
tions a functional model of PG as modulator of hormone
action is emerging. GAGs provide cell-bound reservoirs of
cytokines and other potent hormones that are presented to
receptors on target cells [18]. Some cytokines are protected
from proteolytic degradation when bound to GAG, as is the
case for cell-bound HK [10]. Furthermore, GAG-bound cyto-
kines can be detached from cell surfaces by heparin released
from mast cells during in£ammation [19]. Additionally, shed-
ding proteases or heparinases cleave PG, creating soluble PG
fragments with hormones (e.g. bFGF) still attached [20].
The contact phase factors HK, plasma prekallikrein and
factor XII comprise a plasma kinin-generating system that
complements the tissue-based system comprised of tissue kal-
likrein, low molecular weight kininogen (LK) and kallistatin
[21]. While the cell binding of LK through D3 is well estab-
lished, the recent identi¢cation of a major heparin binding site
Fig. 3. HK interaction with CS in vitro. A: Direct binding of 10 nM biot-HK to CS-A (F), CS-B (S), CS-C (b), HS (R), and glucose (glu,
O). B: Speci¢city of HK binding to covalently immobilized CS-A was probed by incubating 10 nM biot-HK with serial 1:2 dilutions of com-
petitors CS-A (F), CS-B (S), CS-C (b), HS (R), glu (O), HK (P). The starting concentration for each competitor is 200 Wg/ml. C: Speci¢city
of HK binding to covalently immobilized CS-A was probed by incubating 10 nM biot-HK with serial 1:2 dilutions of HK domains MBP^D3
(O), MBP^D5H (E) or MBP (a) ; antibodies KLDC27 (R), KHKH20 (F), or KBK (b) (down from 2 WM each). D: Binding of biot-HK (serial
1:2 dilutions start at 10 nM) to con£uent HEK293t cells in the absence (bu¡er alone, buf) or presence of 500 nM HK (P), HS (R), CSA (S)
or glu (O). Bound biot-HK was quanti¢ed by the streptavidin^peroxidase method.
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in the proteinase inhibitor kallistatin may shed new light on
the role of PG in the tissue-bound system [22]. Indeed CS- and
HS-PG in the extracellular matrix and on surfaces of (for
example) smooth muscle cells may bind to, and assist, kalli-
statin by bringing the inhibitor in close apposition to its target
protease, tissue kallikrein. Thus, similar to the plasma kinin,
the tissue kinin system may use a PG-based platform to con-
trol its powerful actions in glands and neurons.
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Fig. 4. Cross-linking of [125I]HK to the CS portion of PG. GAG
chains of transiently overexpressed decorin-myc (D) or biglycan-myc
(B) PG were photoa⁄nity cross-linked to [125I]HK using ABH.
After lysis of the cells, immunoprecipitation with K-HK (left panel)
or K-myc (right panel) was performed, followed by SDS^PAGE and
autoradiography. Mock-transfected cells served as control (C). Rela-
tive positions of cross-linked products ([125I]HK-PG) and free ligand
([125I]HK) are indicated by solid and open arrowheads, respectively.
Positions of molecular mass standards are shown on the left.
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